Entinostat (MS-275)

Catalog No.S1053 Synonyms: SNDX-275

Entinostat (MS-275) Chemical Structure

Molecular Weight(MW): 376.41

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 270 In stock
USD 770 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 61 Publications

14 Customer Reviews

  • (A) U87 cells were cultured in the presence of DMSO, 1 uM MS-275 alone, 100 ng/ml IFN-λ1 alone, or both for the course of 4 d. Cell numbers were manually determined by hemacytometer counting at the indicated time points. (B, F) Cell proliferation of U87 cells or U87 spheroids in 3D culture with indicated treatment were performed using the WST-1 assay, which measures active cellular metabolism. (C) U87 spheroid formation in 3D culture was photographed at day 14 in culture (representative images are shown; 200x magnification). (D-E) Quantification of the relative sizes and numbers of U87 spheroids in (C). (G) Cell cycle analysis was performed in U87 cells with indicated treatment using propidium iodide staining. Numbers in the histogram show fractions (percent) of sub-G1, N, 2N, and polyploidy from left to right. (H) U87 cells with indicated treatment were stained with Annexin V-FITC and 7-AAD. Numbers indicate the percentage of FITC-positive cells (upper left quadrant). FITC, fluorescein isothiocyanate; 7-AAD, 7-Aminoactinomycin. In all panels, data represent the mean and SEM of at least three experiments.

    PLoS Biol 2014 12, e1001758. Entinostat (MS-275) purchased from Selleck.

    Numerous APC (+) oligodendrocytes (middle upper panel) with ellipsoid nuclei labeled with Sytox (left upper panel) were observed in 8 week old Thy-1 mitoCFP control MONs. NF-200 (+) neurofilaments extended along the MON as linear individual fibers (right upper panel). A period of OGD (60 min) caused a significant loss of APC (+) oligodendrocytes, a gain in the appearance of pyknotic nuclei (dense, brighter nuclei, white arrows, OGD panel), and loss of NF-200 (+) axon structures, which were, replaced with axonal head and bulb formation (white asterisks). Pretreatment with SAHA (1uM) or MS-275 (1uM) effectively preserved APC (+) oligodendrocytes, together with numerous linear individual NF-200 (+) axons. Note fewer pyknotic nuclei (white arrows, SAHA and MS-275 panels) after OGD in MONs treated with SAHA or MS-275.

    J Neurosci 2011 31, 3990-9. Entinostat (MS-275) purchased from Selleck.

  • Inhibition of HDAC1-mediated DNMT1 deacetylation promotes DNMT1 proteasomal degradation. (A) Knockout of HAUSP potentiates HDAC inhibitor (HDACi)-induced DNMT1 degradation. Parental or HAUSP KO DLD1 cells were treated or not with 5 μM HDACi MS-275 for 72 hours and cell lysates were blotted with the indicated antibodies. (B) HDAC inhibition induces DNMT1 ubiquitination. HAUSP WT or KO cells were treated with or without HDACi for 24 hours and MG132 for 12 hours before being harvested to make cell lysates. DNMT1 immunoprecipitates were blotted with an antibody against ubiquitin. Because the abundance of DNMT1 in the HAUSP KO cells is lower than in WT cells, more KO cells were used than WT cells to obtain equal amounts of precipitated DNMT1 proteins. (C) DNMT1 is acetylated after HDACi treatment. DNMT1 immunoprecipitates from cells treated with HDACi were blotted with an antibody against acetylated lysine (Ac-K). (D) A DNMT1 acetylation site mutant is resistant to HDACi-induced degradation. HEK 293 cells were transfected with WT DNMT1 or a DNMT1 mutant lacking four known acetylation sites (K173R, K1113R, K115R, and K117R) and treated with MS-275 for 48 hours and with CHX for 24 hours. Cell lysates were blotted with the indicated antibodies. (E) Knockdown of HDAC1 decreases the abundance of DNMT1. RKO cells were treated with the indicated concentration of doxycycline (Dox) for 48 hours to induce expression of an shRNA directed against HDAC1. Western blots were performed with the indicated antibodies. (F) Knockdown of HDAC1 leads to increased acetylation of DNMT1. RKO cells expressing an inducible HDAC1 shRNA were treated with or without Dox (4 mg/ml) for 36 hours and then with MG132 for 12 hours. DNMT1 immunoprecipitates were blotted with an antibody against Ac-K. Cell lysates were also blotted with antibodies against HDAC1 and b-actin.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

    The E3 ligase UHRF1 ubiquitinates DNMT1. (A) HDAC inhibition enhances DNMT1 interaction with UHRF1. HEK 293 cells were transfected with plasmids expressing Myc-DNMT1 and Flag-UHRF1 and treated with or without MS-275 for 24 hours. Myc-DNMT1 immunoprecipitates were blotted with the indicated antibodies. (B and C) HDAC inhibition enhances the interaction of endogenous DNMT1 and UHRF1. Cells were treated with or without MS-275 and UHRF1 (B) or DNMT1 (C) immunoprecipitates were blotted with the indicated antibodies. (D) UHRF1 ubiquitinates DNMT1. HEK 293 cells were transfected with the indicated plasmids. Antibodies against Myc immunoprecipitates were blotted with antibody against HA to detect ubiquitinated DNMT1. Myc-DNMT1D, DNMT1 mutant lacking the HAUSP-interacting domain. UHRF1DRING, UHRF1 with a RING domain deletion. (E) Knockdown of UHRF1 blocks HDACi-induced DNMT1 degradation. HEK 293 cells were transfected with control siRNA or siRNAs against UHRF1 and treated with or without MS-275. Western blotting was performed with the indicated antibodies. (F) Overexpression of UHRF1 leads to degradation of a DNMT1 mutant lacking the HAUSP-interacting domain (DNMT1D). Full-length DNMT1 or DNMT1D was cotransfected into HEK 293 cells with the indicated expression vectors. Cell lysates were blotted with the indicated antibodies. (G) DNMT1, HAUSP, UHRF1, HDAC1, and PCNA associate with Tip60. Flag-tagged Tip60 immunoprecipitates were blotted with the indicated antibodies.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

  • HAUSP KO cells are more sensitive to HDACi-induced apoptosis.(A) HDAC inhibition induces apoptosis in HAUSP KO cells.HAUSP WT or KO cells were treated with or without MS-275 at the indicated concentration for 72 hours, then fixed and stained with propidium iodide. Flow cytometric analyses were used to profile sub-G1, G1, and G2-M cell populations. Apoptotic cells were quantified after the indicated clones were treated with either 5 or 10 μM MS-275. The means and SDs of three independent experiments were plotted (*P<0.001, t test). (B) HDAC inhibition induces apoptosis in HAUSP KO cells but leads to G2-M arrest in WT cells.Cell cycle profiles of HAUSP WT or KOcells that were treated or not with 5 μM MS-275. (C)HDAC inhibition increases the abundance of apoptotic cell markers. The indicated cells were treated with or without MS-275 for 72 hours.Cell lysates were blotted with antibodies against cleaved caspase 3 and β-actin. (D) Ectopic overexpression of DNMT1 in HAUSP KO cells suppresses apoptosis. HAUSP KO clones or HAUSP KO cells inducibly

    overexpressingDNMT1 were treatedwith 10 μM MS-275. Apoptotic cell populations were quantified by fluorescence-activated cell sorting (FACS) analyses (*P < 0.001, t test). Cell lysates from these cells were blotted with the indicated antibodies. (E) HDAC inhibition arrests the growth of HAUSP KO cells. DLD1, HAUSP KO, and KO cells ectopically expressing HAUSP were treated with the indicated concentration of MS-275 for 4 days. Cell numbers were determined and data from eight replicates were plotted (**P <0.001, t test). (FandG) HDACi inhibits tumor xenograft formation ofHAUSP KOcells.Athymic nudemice (five in each group)were injectedsubcutaneously and bilaterallywith cells of the indicated genotypes. Mice were treated with or without MS-275 at 15mg/kg for 4 weeks. Tumors were harvested and photographed (F). Tumor sizes of the indicated groupsweremeasuredweekly and theaveragevolumes at each timepoint were plotted (G).MANOVA analyses were performed to determine whether there was an overall difference of the tumor sizes, as well as whether there was a difference in development over time of tumor sizes between the two groups (P < 0.0001).
     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

    Notch1ICD, Notch2ICD, and Notch3ICD were transduced into human aortic SMCs, which were then treated with HDAC inhibitors TSA or MS-275 or with vehicle DMSO (con). The top 2 rows are different exposures of the same blot to detect the epitope tags on the N ICD constructs. Longer (top row) and shorter ( second row) exposures are shown because t he level of N2ICD expression was lower than that of N1ICD and N3ICD. SMC markers were analyzed and were similarly induced by activation of each Notch r eceptor. Both TSA and MS-275 significantly suppressed the induction of SMC proteins by Notch activation.

    J Am Heart Assoc 2012 1, e000901. Entinostat (MS-275) purchased from Selleck.

  • LSD1 and HDAC inhibitors exhibit synergistic growth inhibition. Cells were simultaneously treated with pargyline or HDAC inhibitors for 48 h.

     

     

    Breast Cancer Res Treat 2012 131, 777-789. Entinostat (MS-275) purchased from Selleck.

    Inhibition of LSD1 activity by HDAC inhibitors. a MDA-MB-231 and MDA-MB-468 cells were exposed to indicated HDAC inhibitors for 24 h.

     

     

    Exp Dermatol 2010 19, 1096-1102. Entinostat (MS-275) purchased from Selleck.

  • Histone acetylation in the spinal cord after HDACI treatment. Histone acetylation in the lumbar spinal cord of mice receiving i.t. SAHA (25 μg) or MS-275 (0.5 μg) for 30 min was analyzed by immunoblot (A, B) and immunofluorescent histochemistry (C) for antigens indicated. Animals receiving i.t. saline were used as control. Images of the H3K9/18ac signals in the left half of the lumbar spinal cord are shown in the first row in C. Immunosignals of indicated antigens in the superficial dorsal horn are presented in the rest rows in C.

    Mol Pain 2010 6, 51. Entinostat (MS-275) purchased from Selleck.

    B. Confluent quiescent foreskin fibroblasts were treated with HDAC1 inhibitor or vehicle for 24 hours. Type I procollagen protein levels in whole cell lysates were determined by immunoblotting. A representative result of three independent experiments is shown. The band density was evaluated by densitometry. C. Under the same conditions, mRNA levels of the α1(I) collagen (COL1A1) gene were determined using reverse transcription quantitative real-time PCR. The graph represents -fold change in COL1A1 mRNA levels in comparison to unstimulated controls, which were arbitrarily set at 100. The mean and SD from three separate experiments are shown. * p<0.05 versus control cells treated with vehicle.

    PLoS One 2013 8, e74930. Entinostat (MS-275) purchased from Selleck.

  •  

    HDAC inhibition increases SMN-luciferase reporter mRNA levels. qRT-PCR was used to measure increases of SMN-luciferase mRNA following treatment with HDAC inhibitors. Fold increase of mRNA was normalized to GAPDH.

    Biochem Bioph Res Co 2010 414, 25-30. Entinostat (MS-275) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM MS-275 was added.

     

     

    2011 Dr. Zhang of Tianjin Medical University. Entinostat (MS-275) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
Targets
HDAC1 [2]
(Cell-free assay)
HDAC3 [2]
(Cell-free assay)
0.51 μM 1.7 μM
In vitro

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. [1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. [2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 M4\QW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFToZlVKSzVyPUCuNFYyKM7:TR?= MoLzV2FPT0WU
ALL-PO NEn6TVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwME[zOVUh|ryP NXz3cXMyW0GQR1XS
697 MmXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\tTWM2OD1yLkC5PVc3KM7:TR?= NXjPdGJXW0GQR1XS
NCI-H748 NH3ZWI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\hSJNuUUN3ME2wMlExOzN2IN88US=> NGnRVI9USU6JRWK=
NKM-1 NYLHToJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XvXmlEPTB;MD6xNFkyOiEQvF2= MVXTRW5ITVJ?
ES1 NYrq[JVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTBwMUGyOVUh|ryP NH75ZWlUSU6JRWK=
NCI-H1963 Ml:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2D0U2lEPTB;MD6xNVU4QSEQvF2= M2rQXHNCVkeHUh?=
NCI-H1417 M1;zXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvaTWM2OD1yLkGyPVc1KM7:TR?= M4nNdHNCVkeHUh?=
NEC8 NGLOdo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjCOFZKSzVyPUCuNVM2OjdizszN MmjWV2FPT0WU
CRO-AP2 NUHnXnFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jOUGlEPTB;MD6xOlg5QSEQvF2= M4HoNHNCVkeHUh?=
A3-KAW NFX0VGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mon4TWM2OD1yLkG3OlI4KM7:TR?= NX;oSnpnW0GQR1XS
SF539 NHrSNHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXkUHFKSzVyPUCuNVk2QTNizszN M4nVfnNCVkeHUh?=
NOS-1 NULKPGY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVuyOJp6UUN3ME2wMlE6PjF7IN88US=> MofLV2FPT0WU
NTERA-S-cl-D1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\QTWM2OD1yLkKwNVE{KM7:TR?= M1qxWnNCVkeHUh?=
COR-L88 NUS2Spo1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLQTWM2OD1yLkKyPVU6KM7:TR?= NHzJc4ZUSU6JRWK=
EM-2 Mo\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7sUZVYUUN3ME2wMlI1ODd7IN88US=> MUPTRW5ITVJ?
KARPAS-45 NWLZ[W5DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHrWGp3UUN3ME2wMlI4QDN|IN88US=> MUjTRW5ITVJ?
DSH1 NGrhdlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUn6bIZYUUN3ME2wMlI5PzB6IN88US=> MWTTRW5ITVJ?
HT-144 M{\rfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnyyTWM2OD1yLkOwNlU3KM7:TR?= NVPDVYZmW0GQR1XS
ATN-1 M{Hu[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHxTWM2OD1yLkOwOVc3KM7:TR?= NUX4SJdbW0GQR1XS
HEL Mk[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTBwM{GzOFgh|ryP Mn7QV2FPT0WU
NB12 NYPTd4ZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;4SZFLUUN3ME2wMlMyPzV4IN88US=> MYXTRW5ITVJ?
LU-139 M17UU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXqwRYlOUUN3ME2wMlM{PTFizszN NHv6ellUSU6JRWK=
J-RT3-T3-5 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3z6cGlEPTB;MD6zN|cyPiEQvF2= NH;VXXNUSU6JRWK=
MOLT-13 M2TnVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTBwM{O4NUDPxE1? MnmzV2FPT0WU
SR NHz0XohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnPXGs1UUN3ME2wMlM1OjZzIN88US=> M3n2bXNCVkeHUh?=
CMK MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvLeZNKSzVyPUCuN|U4OjdizszN MW\TRW5ITVJ?
ES8 Mm\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHnTWM2OD1yLkO2NFIzKM7:TR?= MXzTRW5ITVJ?
LB647-SCLC MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTBwM{[3N{DPxE1? NUnxcpJzW0GQR1XS
TE-8 NHzESJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofaTWM2OD1yLkO2PVM2KM7:TR?= NX3O[IhLW0GQR1XS
BV-173 NXuzemExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnHXYNKSzVyPUCuN|cyOjFizszN Mof0V2FPT0WU
DEL Mk\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFS4d|VKSzVyPUCuN|c1QDdizszN MVvTRW5ITVJ?
ARH-77 Ml7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTBwM{ixPVMh|ryP M2HBWHNCVkeHUh?=
NCCIT Mk\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fIZmlEPTB;MD6zPFY1QSEQvF2= NV:1XI5oW0GQR1XS
RPMI-8402 NH;LSWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLsT45oUUN3ME2wMlM5PzBzIN88US=> MYPTRW5ITVJ?
MONO-MAC-6 MnfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXj0VWxqUUN3ME2wMlM5Pzd4IN88US=> MWTTRW5ITVJ?
SK-MM-2 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTBwM{m4Olgh|ryP NWP1V4NKW0GQR1XS
CHP-126 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHETWM2OD1yLkSwNlMyKM7:TR?= M17Ve3NCVkeHUh?=
A101D NWjr[VVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7Kb|lmUUN3ME2wMlQxOyEQvF2= MVHTRW5ITVJ?
SCH NFzkd5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoW4TWM2OD1yLkSwN|QzKM7:TR?= MkHzV2FPT0WU
NMC-G1 NI\iTnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fNVWlEPTB;MD60NFM3PyEQvF2= NFy3O4ZUSU6JRWK=
NCI-H209 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTBwNEC2NVMh|ryP NFrCc2RUSU6JRWK=
MOLT-16 M3HUd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHSXVlKSzVyPUCuOFExOTdizszN NYj0R|ExW0GQR1XS
RPMI-6666 NVzZT2RoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrVfWVKSzVyPUCuOFEyOiEQvF2= Mn;2V2FPT0WU
OPM-2 NHj4Z3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXv6d3RDUUN3ME2wMlQyPTF|IN88US=> Mln5V2FPT0WU
MRK-nu-1 MnLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXpTWM2OD1yLkSzNVU{KM7:TR?= NYnybItjW0GQR1XS
BC-1 M3W4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DtXWlEPTB;MD60N|QxOyEQvF2= M1i2U3NCVkeHUh?=
MHH-NB-11 NG[3dIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3MWYxMUUN3ME2wMlQ{PDV|IN88US=> M2jPRXNCVkeHUh?=
Ramos-2G6-4C10 M3\QbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITkPJFKSzVyPUCuOFM5QTdizszN M3vmZnNCVkeHUh?=
LS-513 NWjJb3FGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUT6fGlpUUN3ME2wMlQ1PTBzIN88US=> M13QOnNCVkeHUh?=
K5 MljIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoC5TWM2OD1yLkS3NFI2KM7:TR?= MVLTRW5ITVJ?
HOP-62 NHzHcGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmOxTWM2OD1yLkS4N|U5KM7:TR?= MWPTRW5ITVJ?
NCI-H187 NFHud|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjLZXdmUUN3ME2wMlQ6OjJ5IN88US=> MXTTRW5ITVJ?
BE-13 NUC5[ZFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Xje2lEPTB;MD60PVY3OSEQvF2= M2LJcHNCVkeHUh?=
HC-1 NXPITpFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTBwNUC0O|Mh|ryP MkXVV2FPT0WU
ACN NXXaeZZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\zTWM2OD1yLkWxNFI5KM7:TR?= NE\0fVBUSU6JRWK=
HCC1599 NULRc3RoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{iwb2lEPTB;MD61NVU4KM7:TR?= MVfTRW5ITVJ?
MV-4-11 M1fldGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHvfG82UUN3ME2wMlU{ODRzIN88US=> NF;YelZUSU6JRWK=
LC-2-ad M37yOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmO2TWM2OD1yLkWzOlY{KM7:TR?= NV;kfZprW0GQR1XS
HL-60 M3HTPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnhTWM2OD1yLkW0NlYyKM7:TR?= NWPDUHZ5W0GQR1XS
NB17 Mn3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfSeXFKSzVyPUCuOVQ{QCEQvF2= MkXiV2FPT0WU
TE-1 M2nxTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHWOWlKSzVyPUCuOVU{ODZizszN M4PBNHNCVkeHUh?=
NCI-H524 NFHCe3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnvboxKSzVyPUCuOVU1ODFizszN M4DaTnNCVkeHUh?=
MZ7-mel NEXBRYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTBwNU[xNFUh|ryP MW\TRW5ITVJ?
L-363 MkC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LMXmlEPTB;MD61OlY2PyEQvF2= MWLTRW5ITVJ?
BL-41 M{[xeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTBwNU[4PFkh|ryP M1PydHNCVkeHUh?=
LU-134-A M1rVPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTBwNUewO|Mh|ryP Mmj3V2FPT0WU
SIG-M5 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTBwNUe4OFgh|ryP NYHZVINjW0GQR1XS
ONS-76 M{HofWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3QTWM2OD1yLkW4NlQzKM7:TR?= M3\mcnNCVkeHUh?=
KARPAS-299 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3OTWNKSzVyPUCuOVg2ODRizszN M4HxbnNCVkeHUh?=
DU-4475 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTBwNUi3NFMh|ryP NULDcmM6W0GQR1XS
NB69 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37iTmlEPTB;MD61PVgzPSEQvF2= M4G0XHNCVkeHUh?=
MHH-PREB-1 M2fLNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYn4blN{UUN3ME2wMlYxPzF7IN88US=> Mn3RV2FPT0WU
LU-165 NEX1RWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTQb3RCUUN3ME2wMlYyQDF{IN88US=> M3j4WnNCVkeHUh?=
LOUCY MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjiRoMyUUN3ME2wMlY{OzZ2IN88US=> NIXa[4FUSU6JRWK=
NCI-H526 NYexO3FqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3n6fGlEPTB;MD62N|U1OSEQvF2= NIf4T4dUSU6JRWK=
KE-37 M1[4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmX4TWM2OD1yLk[0Nlc3KM7:TR?= NIjPcpdUSU6JRWK=
NALM-6 NGHYfW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLWTWM2OD1yLk[0PFYh|ryP MYrTRW5ITVJ?
CW-2 NGHtXnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPwTFBNUUN3ME2wMlY2Pzl2IN88US=> MVXTRW5ITVJ?
SU-DHL-1 NITKeINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fpb2lEPTB;MD62OVk1PyEQvF2= M37mW3NCVkeHUh?=
NB13 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTBwNk[4NVch|ryP M2[x[HNCVkeHUh?=
QIMR-WIL NH;2VIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1G4[WlEPTB;MD62PFM1OyEQvF2= M4i0VnNCVkeHUh?=
ECC12 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3ixZmlEPTB;MD63NFA5PiEQvF2= NHz1PW1USU6JRWK=
KALS-1 NHXOcHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvFTWM2OD1yLkewOFkzKM7:TR?= M3fqZXNCVkeHUh?=
COR-L279 MlXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\5e254UUN3ME2wMlcxQTl4IN88US=> MVTTRW5ITVJ?
NB14 M{KwbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTBwN{K2NVch|ryP MXLTRW5ITVJ?
CCRF-CEM NVLUcoF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPtdZNKSzVyPUCuO|Q3PjFizszN MUXTRW5ITVJ?
SW954 M3mz[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jpdmlEPTB;MD63OVk6QSEQvF2= NH\0O5FUSU6JRWK=
IST-SL1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwN{ezOFgh|ryP M3fxenNCVkeHUh?=
LAMA-84 NH3RXFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjYTpBKUUN3ME2wMlc4PTZ5IN88US=> MWnTRW5ITVJ?
Daudi NYK5OIlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHMTWM2OD1yLke3OlgyKM7:TR?= NUG5d4pUW0GQR1XS
BC-3 M1rxc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPmN3hKSzVyPUCuO|g{ODhizszN NIDaVGtUSU6JRWK=
HCC2998 M4n4b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLnTWM2OD1yLke4N|Yh|ryP MkK2V2FPT0WU
NCI-H69 M2[wd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXi0dJhtUUN3ME2wMlgxOTR5IN88US=> NVnwfFJ4W0GQR1XS
CPC-N NYnVe25zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTBwOEC1NlQh|ryP M4X1OnNCVkeHUh?=
NOMO-1 NVftOI5kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYS5NpdKUUN3ME2wMlgyODh2IN88US=> NV7kdGNNW0GQR1XS
CESS Mm[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPBSXZKSzVyPUCuPFEyQTdizszN MVjTRW5ITVJ?
LC4-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXFelM{UUN3ME2wMlg1ODB5IN88US=> MlPjV2FPT0WU
BL-70 NXLJSIhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DsbWlEPTB;MD64OVcxOiEQvF2= NH3KRWlUSU6JRWK=
ES4 NV7KSlRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTBwOEW4Olgh|ryP NVKw[Y1WW0GQR1XS
HCE-T MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnx[25WUUN3ME2wMlg4OTdzIN88US=> MWXTRW5ITVJ?
JAR MlPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXPZmpKSzVyPUCuPFc5OjdizszN NHPWZ4FUSU6JRWK=
ST486 NVvmXpliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3ETWM2OD1yLki3PVE4KM7:TR?= M3nGbnNCVkeHUh?=
KS-1 MkTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjBeWlKSzVyPUCuPFgxQTZizszN M4ftbnNCVkeHUh?=
GDM-1 MnXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIe2XndKSzVyPUCuPFg3QDdizszN NGnleoRUSU6JRWK=
EHEB MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXhRVNtUUN3ME2wMlkzPTh3IN88US=> MX7TRW5ITVJ?
LB2518-MEL NGi3cYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjCO45KSzVyPUCuPVMzQDRizszN M17XWHNCVkeHUh?=
GOTO NV[xU|J3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTBwOUWwO|Yh|ryP MVHTRW5ITVJ?
LXF-289 MlXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEK3cYxKSzVyPUCuPVU6ODFizszN MoXFV2FPT0WU
ES6 NWHjV5J7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzKSGx4UUN3ME2wMlk3PDN5IN88US=> MkDRV2FPT0WU
OS-RC-2 M4\Tfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTBwOU[4N{DPxE1? NW[5d|NOW0GQR1XS
DMS-153 NVG1N2wzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PuPWlEPTB;MD65O|Q3QSEQvF2= NEXtemVUSU6JRWK=
SK-PN-DW MmL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTBwOUe4N|Eh|ryP MXnTRW5ITVJ?
HH MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHYOmpNUUN3ME2wMlk5QTV7IN88US=> MoLoV2FPT0WU
SH-4 Mm\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfoTWM2OD1zLkCyOFEh|ryP MknHV2FPT0WU
MOLT-4 NGPzcIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTFwMEO0OVQh|ryP NHvmVGJUSU6JRWK=
TGW MmLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;iTWM2OD1zLkC3Olc2KM7:TR?= MnG3V2FPT0WU
L-540 MlHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rVbWlEPTB;MT6xNFYxPCEQvF2= M4rzOHNCVkeHUh?=
PF-382 NE\INnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7yS49KSzVyPUGuNVE2OTNizszN M{LVdnNCVkeHUh?=
LC-1F NWi4Z2RlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfZcJNKSzVyPUGuNVIxODdizszN MXHTRW5ITVJ?
OVCAR-4 NFWzPFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjpeplKSzVyPUGuNVMyPjVizszN NVHXWWdqW0GQR1XS
A4-Fuk NFT2TpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zld2lEPTB;MT6xOVM3PCEQvF2= MXfTRW5ITVJ?
HCC2218 MlfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTFwMU[2OFEh|ryP MUXTRW5ITVJ?
HAL-01 M2W2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;CZ2lEPTB;MT6xOlk1OyEQvF2= MWTTRW5ITVJ?
IST-MEL1 NFG5[pBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHrTWM2OD1zLkG3OlU6KM7:TR?= MmGwV2FPT0WU
NCI-H719 M1m4e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTFwMUe4PVgh|ryP M{nnRXNCVkeHUh?=
EVSA-T NFXqNodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTFwMUixNVQh|ryP M{W1e3NCVkeHUh?=
SK-NEP-1 M4rrTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTFwMkCyOlYh|ryP M2m4NXNCVkeHUh?=
OCUB-M NFroTGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfjOZFWUUN3ME2xMlIyPDh7IN88US=> NXnvZYRxW0GQR1XS
MEG-01 Ml[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTFwMkKxNVgh|ryP MXTTRW5ITVJ?
no-10 NXHSZ|E6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnS4TWM2OD1zLkKzNVEzKM7:TR?= NEDvOnlUSU6JRWK=
MHH-CALL-2 M3fpO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHVZ5RHUUN3ME2xMlI1PzJzIN88US=> NG[4UlBUSU6JRWK=
SK-N-DZ MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HUcWlEPTB;MT6yOFc4PiEQvF2= MVzTRW5ITVJ?
SCLC-21H M1exT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjSOlBKSzVyPUGuNlY1PzhizszN MoDBV2FPT0WU
CTV-1 NU\2TnFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknlTWM2OD1zLkK3OFI2KM7:TR?= MmfuV2FPT0WU
NB1 M4TUPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fYeWlEPTB;MT6yO|c{OiEQvF2= MkexV2FPT0WU
NCI-H64 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPHWYlKSzVyPUGuNlg1PjJizszN NY\nZVZvW0GQR1XS
MDA-MB-134-VI NYLkeIs1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnG3TWM2OD1zLkK4OVc4KM7:TR?= NGTEcpFUSU6JRWK=
LB2241-RCC M2O3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXoSJBKSzVyPUGuNlg3PjNizszN M3zLTXNCVkeHUh?=
8-MG-BA MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\STWM2OD1zLkK4PFY3KM7:TR?= M2S0[3NCVkeHUh?=
LP-1 NWXwOIx{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILlcJBKSzVyPUGuNlk6PDdizszN MonIV2FPT0WU
LS-411N NY[xTVBIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XHfWlEPTB;MT6zNFk6QCEQvF2= M4\DVXNCVkeHUh?=
CAL-148 M{PXcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLGTWM2OD1zLkOyOVQzKM7:TR?= MYTTRW5ITVJ?
NCI-H2171 NW\UTJBIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjyNnpCUUN3ME2xMlM1PTB{IN88US=> NYfme2x7W0GQR1XS
JiyoyeP-2003 NVvPenNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fJR2lEPTB;MT6zOVM6KM7:TR?= NVyw[VBEW0GQR1XS
NCI-H2107 NF\ZeWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2e4RWlEPTB;MT6zOVg5OyEQvF2= Mlm3V2FPT0WU
BB30-HNC MoGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDRZY9KSzVyPUGuN|g6PzhizszN M1foOnNCVkeHUh?=
K-562 MmfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\ufFlKSzVyPUGuN|kzOTlizszN Mmf3V2FPT0WU
PSN1 NYXOepNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTFwNEKyPFch|ryP NUWw[VR4W0GQR1XS
HCC2157 NVHXdFBbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nWbGlEPTB;MT60NlY6OSEQvF2= MlX0V2FPT0WU
SBC-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXjblQ4UUN3ME2xMlQzPzRzIN88US=> NEix[GNUSU6JRWK=
MC116 NYLjS5o6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTFwNEO2NVUh|ryP M3vxWnNCVkeHUh?=
KARPAS-422 NWnxPYhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHTU|JKSzVyPUGuOFU{PThizszN NXP0T2MxW0GQR1XS
LB996-RCC NGny[GlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnm5TWM2OD1zLkS3NVA{KM7:TR?= MmGwV2FPT0WU
MSTO-211H M{j2VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofzTWM2OD1zLkS3PVg4KM7:TR?= NYr0VmFyW0GQR1XS
BT-474 M1nW[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmf0TWM2OD1zLkWxO|Y1KM7:TR?= MYjTRW5ITVJ?
A388 M2\mUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XVbWlEPTB;MT61NVk1PSEQvF2= NYfrNmRiW0GQR1XS
SJSA-1 NHjFTm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LwO2lEPTB;MT61NlI3KM7:TR?= MmTEV2FPT0WU
COLO-829 M2TxSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnBc5RKSzVyPUGuOVM2PjRizszN M4e5fHNCVkeHUh?=
KM-H2 MmDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPoTWM2OD1zLkW2Olch|ryP NFzRW2lUSU6JRWK=
GR-ST M1[yRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLVTWM2OD1zLkW2PFIh|ryP NGO5THNUSU6JRWK=
RPMI-8866 NYLnPXZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvNb2tKSzVyPUGuOlAyPDRizszN MVrTRW5ITVJ?
KG-1 MmXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTFwNkG5NFEh|ryP MXTTRW5ITVJ?
NCI-H82 NUW0[5I3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjjTWM2OD1zLk[zOFA3KM7:TR?= NHT2coVUSU6JRWK=
LB1047-RCC NX36XWF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTFwNkO0OVkh|ryP MlG2V2FPT0WU
KM12 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnNTWM2OD1zLk[0O{DPxE1? MkT1V2FPT0WU
NB5 MlvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\E[|hKSzVyPUGuOlU3PzdizszN NF7sN4NUSU6JRWK=
HDLM-2 MkTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPwTWM2OD1zLk[4NlgyKM7:TR?= Ml;uV2FPT0WU
KU812 NUXVUIZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILRN29KSzVyPUGuOlk3ODVizszN NV23UHltW0GQR1XS
DB NVO1e5BUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVmxd4d{UUN3ME2xMlcxOzV|IN88US=> MUfTRW5ITVJ?
HD-MY-Z MorxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTFwN{WyN|Qh|ryP NGTLN3hUSU6JRWK=
KURAMOCHI NGDK[|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFu0TolKSzVyPUGuO|czODdizszN NEHwSo9USU6JRWK=
ETK-1 NXLqc2N7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTFwN{i4O|kh|ryP NUP0RVNJW0GQR1XS
SK-UT-1 NHWzb2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTFwN{mzPFgh|ryP NYLDUGhMW0GQR1XS
HUTU-80 NFiyXWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTFwN{m1NFgh|ryP M{ezTXNCVkeHUh?=
ES7 M3;vTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGr6ZoxKSzVyPUGuPFA{ODJizszN NIK4TG5USU6JRWK=
SW872 NFvwZZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfsfXlKSzVyPUGuPFE{QTVizszN MoLaV2FPT0WU
TK10 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Di[2lEPTB;MT64N|ExQCEQvF2= NVjEXoZQW0GQR1XS
LB831-BLC MlezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLtN4ZTUUN3ME2xMlg{PTZ|IN88US=> M4fnfXNCVkeHUh?=
TE-9 M1Toc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrjTWM2OD1zLki0OFIzKM7:TR?= MnvqV2FPT0WU
MLMA NXvFZ|R6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\iSm9MUUN3ME2xMlg5OjN2IN88US=> NHPKPWhUSU6JRWK=
D-542MG NF7OSphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHWwSIlKSzVyPUGuPFk{PzNizszN NEiyRoJUSU6JRWK=
EW-16 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTFwOUK3NkDPxE1? M2XrNXNCVkeHUh?=
LOXIMVI NYDKRVFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TYO2lEPTB;MT65N|I5KM7:TR?= MXTTRW5ITVJ?
GB-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnMSWlDUUN3ME2xMlk{QDZ4IN88US=> M2OwdnNCVkeHUh?=
IST-SL2 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV6xS2pDUUN3ME2yMlAxOjZ{IN88US=> MYfTRW5ITVJ?
LAN-6 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfvTWM2OD1{LkCxPVY3KM7:TR?= Mn:yV2FPT0WU
NCI-H510A NHPkN2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrYRmg{UUN3ME2yMlA1PTB{IN88US=> NWi1U2VDW0GQR1XS
NCI-H1092 M1G0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTJwMEWxNlQh|ryP MYHTRW5ITVJ?
HT MkjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLKTWM2OD1{LkGwOFU1KM7:TR?= NXiwco1RW0GQR1XS
RL95-2 MlHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mly4TWM2OD1{LkGxOFgzKM7:TR?= M3K2XHNCVkeHUh?=
NCI-H1355 NELtN2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTudGpKSzVyPUKuNVE4QTJizszN NWPjV3BLW0GQR1XS
NCI-H720 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojGTWM2OD1{LkG2PFc{KM7:TR?= M3\YdXNCVkeHUh?=
NCI-H1522 NHLHcIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfKbXdyUUN3ME2yMlIyPzJ|IN88US=> NH\Nc5BUSU6JRWK=
LB373-MEL-D MojSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEmwWVlKSzVyPUKuNlY6ODJizszN NEPER4pUSU6JRWK=
DG-75 NWqzV28zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\DTWM2OD1{LkK3NVQ5KM7:TR?= M3jIPXNCVkeHUh?=
ML-2 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmriTWM2OD1{LkOyPFU2KM7:TR?= Mor2V2FPT0WU
SF126 NVj2PGRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jETGlEPTB;Mj6zN|A6PCEQvF2= NXLFN4poW0GQR1XS
MPP-89 MkjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTncmVKSzVyPUKuN|MyPDVizszN MnXnV2FPT0WU
NCI-H345 MojxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofsTWM2OD1{LkOzNlc4KM7:TR?= NWTZWWdoW0GQR1XS
LS-123 MmftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrITWM2OD1{LkO0PVM3KM7:TR?= Ml3rV2FPT0WU
NB10 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWK5PVlvUUN3ME2yMlQyODl{IN88US=> NXT6NpFSW0GQR1XS
CGTH-W-1 NHPrfmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3f5fWlEPTB;Mj60NlI3PyEQvF2= MWPTRW5ITVJ?
CP66-MEL NI\jN2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDyd4lKSzVyPUKuOFc4PyEQvF2= MnjaV2FPT0WU
L-428 NEXxcIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTJwNEi1NlEh|ryP NWftc5E4W0GQR1XS
DMS-79 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTJwNUSxNFMh|ryP MWnTRW5ITVJ?
NCI-H1882 M2X4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWW4VGNNUUN3ME2yMlY4PTZ{IN88US=> M4DNenNCVkeHUh?=
KGN M4\OXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7UPGUxUUN3ME2yMlc3QDd4IN88US=> Mn;oV2FPT0WU
EW-1 MljRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrXfGp[UUN3ME2yMlc4ODh|IN88US=> NVroWIJOW0GQR1XS
U-266 NIHqSZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTJwOES4NlMh|ryP NGThb49USU6JRWK=
COLO-320-HSR MlfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjjRnpKSzVyPUKuPFU3PDFizszN NXW4bnZIW0GQR1XS
KMOE-2 NVfWblJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzCWJZKSzVyPUKuPFc4OTFizszN MX7TRW5ITVJ?
BB49-HNC MljlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jyPGlEPTB;Mj65NlQ5KM7:TR?= NEnXNZVUSU6JRWK=
GI-1 M1K1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmGwTWM2OD1{LkmyPVU4KM7:TR?= MVvTRW5ITVJ?
NCI-H1304 NF7leGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmKxTWM2OD1|LkCwOVEyKM7:TR?= MVXTRW5ITVJ?
NCI-H2227 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTNwMEKwO|kh|ryP M{LncXNCVkeHUh?=
U-87-MG NWW2RXNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjCNJdKSzVyPUOuNFM2OTNizszN MXnTRW5ITVJ?
NCI-H747 M{DHfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TEVWlEPTB;Mz6wOVIxPiEQvF2= M{LoNXNCVkeHUh?=
CTB-1 NXTve3U5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LZNGlEPTB;Mz6wOVM4PiEQvF2= MVvTRW5ITVJ?
RPMI-8226 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nqbWlEPTB;Mz6xOFM4QCEQvF2= MlPEV2FPT0WU
NCI-H2141 NVKyTGxMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUO0OHF5UUN3ME2zMlE3PTZ4IN88US=> NFqwNodUSU6JRWK=
IST-MES1 NEXy[WVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnyfIpJUUN3ME2zMlE5Ojd7IN88US=> M{jpdHNCVkeHUh?=
TE-5 NHmzdVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWD2NoJRUUN3ME2zMlIyOzR{IN88US=> NWLVXlFiW0GQR1XS
UACC-257 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLhZXI4UUN3ME2zMlQ{PjV7IN88US=> M{D0[nNCVkeHUh?=
SK-N-FI NXfkN3RoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTNwNEWyNlch|ryP M3XlRnNCVkeHUh?=
MFH-ino M4nkR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXwZZNKSzVyPUOuOFY2QDlizszN NIT2SVhUSU6JRWK=
SF268 Mn6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUOwUWFmUUN3ME2zMlQ5OTd2IN88US=> MlHWV2FPT0WU
TE-12 NI\leYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEiwTVRKSzVyPUOuOVE3QTlizszN MUPTRW5ITVJ?
NB6 NUi2enpsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPSW|lKSzVyPUOuOVU2PjNizszN M2\zTXNCVkeHUh?=
DJM-1 NXzO[4N1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTNwNUm4PVkh|ryP NHTNTYRUSU6JRWK=
MZ1-PC M2DvXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HKVmlEPTB;Mz62NVYzPCEQvF2= MkHSV2FPT0WU
OCI-AML2 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M160d2lEPTB;Mz62NlY4OSEQvF2= NXv2NoxnW0GQR1XS
NCI-H1155 MlrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFr6e5NKSzVyPUOuO|A6PDdizszN MkPCV2FPT0WU
RKO NVjlUVcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLZTWM2OD1|Lke3NVg6KM7:TR?= NF7afYxUSU6JRWK=
ECC4 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUG2NnhvUUN3ME2zMlk4OTl3IN88US=> M4rLUXNCVkeHUh?=
BB65-RCC M3TVTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTNwOUe1OFch|ryP MWfTRW5ITVJ?
EB-3 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTNwOUm2N|Mh|ryP MUHTRW5ITVJ?
SHP-77 NH\IS2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTRwMEC1NlQh|ryP MlXEV2FPT0WU
NCI-H2196 MkLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzZSVBKSzVyPUSuNFU3OjVizszN MkfJV2FPT0WU
GI-ME-N Ml;jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTRwME[zPVkh|ryP MYnTRW5ITVJ?
MN-60 MkTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\oTWM2OD12LkGwPFch|ryP M4fLcXNCVkeHUh?=
NCI-H1694 MofWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;zboNKSzVyPUSuNVM1ODVizszN MVvTRW5ITVJ?
LU-65 NGrxToxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFi2S2dKSzVyPUSuNVU{OzJizszN MYLTRW5ITVJ?
NCI-H1436 MlLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoT6TWM2OD12LkG4N|M{KM7:TR?= NXn6TGZ5W0GQR1XS
KINGS-1 MnvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF:3TVlKSzVyPUSuN|E1OzJizszN M2PzSXNCVkeHUh?=
GT3TKB NGfERnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrPdnlbUUN3ME20MlM{OjZ6IN88US=> Ml7QV2FPT0WU
Becker M2rvdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jibGlEPTB;ND6zO|MyOiEQvF2= MVTTRW5ITVJ?
HCC1187 MoLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rwcGlEPTB;ND64PVY2PyEQvF2= M3KwUnNCVkeHUh?=
D-502MG MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\RO4JGUUN3ME21MlAxPDF4IN88US=> MmG4V2FPT0WU
VA-ES-BJ NGP4[pZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7tSmtKSzVyPUWuNVM4PzhizszN Mkn6V2FPT0WU
NB7 MkjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XEc2lEPTB;NT6xOFEyOiEQvF2= M3\FXnNCVkeHUh?=
SW962 NXrtWG1LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGi3d5ZKSzVyPUWuN|g5OTRizszN M1XEOHNCVkeHUh?=
no-11 MmjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTVwN{[zOFMh|ryP M2G4XnNCVkeHUh?=
KNS-81-FD MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmroTWM2OD13LkmwOlk1KM7:TR?= NH;USodUSU6JRWK=
COLO-684 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\MZ4VKSzVyPUWuPVk1QTRizszN Mn23V2FPT0WU
D-263MG NF\1fZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXH4blNYUUN3ME22MlA5QDl3IN88US=> NInaTGhUSU6JRWK=
EW-24 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTOeY5wUUN3ME22MlI5PTFizszN MYjTRW5ITVJ?
TE-10 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\Jc2lEPTB;Nj60NlYzOyEQvF2= M3;aSXNCVkeHUh?=
EKVX NV;0[5hqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfPTWM2OD14LkS2N|IyKM7:TR?= M2PTV3NCVkeHUh?=
NCI-H1648 MmjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\HXnVKSzVyPU[uOlc2PTdizszN NWnhdY1IW0GQR1XS
LB771-HNC NHzhfVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mor3TWM2OD14LkmyN|AyKM7:TR?= NY[5PJZKW0GQR1XS
SK-MEL-1 M{XlRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\m[WlEPTB;OD6xN|E3PiEQvF2= MojuV2FPT0WU
COLO-668 NWWyS|A4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRThwMke3PFYh|ryP M1:xNHNCVkeHUh?=
EW-12 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljNTWM2OD16LkSwPFA{KM7:TR?= NYKyXXE4W0GQR1XS
A253 M370VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zyeGlEPTB;OD64OFY3OSEQvF2= MWXTRW5ITVJ?
NCI-H2126 Mme2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHOSGdKSzVyPUiuPFk{OTlizszN M3\0cHNCVkeHUh?=
Calu-6 NUnEbpZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7se5lKSzVyPUiuPVkxPDJizszN MVrTRW5ITVJ?
NCI-H23 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TBc2lEPTB;OT6xO|c1PiEQvF2= NIHPd4hUSU6JRWK=
WSU-NHL NEDqfFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mny2TWM2OD17Lke3OFc5KM7:TR?= NGrLb5dUSU6JRWK=
MMAC-SF MoXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLkTWM2OD17Lkm3PVA1KM7:TR?= NHznRYlUSU6JRWK=
SK-LMS-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jvV2lEPTB;MUCuNlg{PCEQvF2= NW\GWnJCW0GQR1XS
GCIY NHvIe4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlWyTWM2OD1zMD61PVI1KM7:TR?= MmTuV2FPT0WU
TE-15 MmrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nkPGlEPTB;MUGuOlAxPCEQvF2= NIf0NXFUSU6JRWK=
EoL-1-cell MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTFzLke2PFIh|ryP MkLrV2FPT0WU
NCI-H2081 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnv4TWM2OD1zMT63O|g3KM7:TR?= MnHmV2FPT0WU
EW-3 NFzKNo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEP2dFhKSzVyPUGyMlI1PjNizszN NV[5OWk3W0GQR1XS
CAS-1 MnjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVW1boExUUN3ME2xNk4{PjNzIN88US=> M1fMVHNCVkeHUh?=
C2BBe1 M3\RSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTF{Lk[xN|Eh|ryP M3fLZ3NCVkeHUh?=
D-247MG MlTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYmzTZBHUUN3ME2xNk44QTV{IN88US=> Mn\WV2FPT0WU
NCI-SNU-5 NH;WZ5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzPd4tKSzVyPUGyMlgxOTNizszN NH7GNHNUSU6JRWK=
LS-1034 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTF2LkO5O|Uh|ryP MlW1V2FPT0WU
EW-18 NFT5O5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTrRZQyUUN3ME2xOE41PDhizszN MkXnV2FPT0WU
Raji M{Xjd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPxTWM2OD1zND61NFQ6KM7:TR?= MlTsV2FPT0WU
D-283MED NEfx[G5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjMTWM2OD1zND62NlcyKM7:TR?= MnuwV2FPT0WU
MZ2-MEL M1nWfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPSTWM2OD1zND65Olk3KM7:TR?= NF[1[3dUSU6JRWK=
NCI-SNU-16 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXvTWM2OD1zNT60OlM{KM7:TR?= Mmr3V2FPT0WU
P30-OHK Mo[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTF5Lke4N|Eh|ryP M3TldHNCVkeHUh?=
RXF393 NYKxcXJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3aTWM2OD1zOT6wNVg3KM7:TR?= MnPtV2FPT0WU
NCI-H1395 MmHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jucGlEPTB;MkCuOlcxOyEQvF2= NYm3bpY6W0GQR1XS
U-698-M MlTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjZN25KSzVyPUKwMlcxPzVizszN M33SVXNCVkeHUh?=
NCI-SNU-1 M4T3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTuNFd1UUN3ME2yNE44OjJ|IN88US=> MoP2V2FPT0WU
SW684 MlfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\vXWlEPTB;MkGuNVcyPiEQvF2= MY\TRW5ITVJ?
NCI-H716 NIftTG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTaTWM2OD1{MT6zNVU1KM7:TR?= Ml70V2FPT0WU
JVM-2 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTJzLkSxN|Mh|ryP M1nzdXNCVkeHUh?=
NCI-H1581 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjUcldKSzVyPUKyMlQyPDhizszN NUX1TFRLW0GQR1XS
CA46 NH\FZXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3Tr[GlEPTB;M{GuOlk{PiEQvF2= MlHQV2FPT0WU
SNB75 M2n6OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4Swd2lEPTB;M{OuOlUxOyEQvF2= NXG3T3piW0GQR1XS
KNS-42 NV7RUY46T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzCWHZKSzVyPUO1Mlk3OjRizszN MVXTRW5ITVJ?
TUR NIPmWWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzNNplwUUN3ME2zOk4xPTJzIN88US=> MnqyV2FPT0WU
REH Mm\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPLTWM2OD1|Nz64NlEyKM7:TR?= NFuxOG1USU6JRWK=
EW-22 MmSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHyPIhYUUN3ME20Nk4zQDh3IN88US=> M{TYNXNCVkeHUh?=
NCI-H446 NELRUJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjwOopOUUN3ME20Nk44QDV|IN88US=> NYfCe4VyW0GQR1XS
ES3 Ml3SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTR|LkGzN|kh|ryP MYTTRW5ITVJ?
EW-11 MoGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTR2LkiyNVgh|ryP MmHOV2FPT0WU
RH-1 Mln6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTR5LkW4NVIh|ryP M36xdHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. [1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. [4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. [5]

Protocol

Kinase Assay:

[6]

+ Expand

Standard HDAC Assays:

Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. Km and Vmax values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
Cell Research:

[2]

+ Expand
  • Cell lines: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells
  • Concentrations: ~ 10 μM
  • Incubation Time: 3 days
  • Method:

    Cancer cells (5 × 103) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO2-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na2HPO4 is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice.
  • Formulation: Dissolved with 0.05 N HCl, 0.1% Tween 80
  • Dosages: 12.3, 24.5 and 49 mg/kg
  • Administration: Administered orally once daily 5 days per week for 4 weeks
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 75 mg/mL (199.25 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 2% DMSO+30% PEG 300 10mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 376.41
Formula

C21H20N4O3

CAS No. 209783-80-2
Storage powder
in solvent
Synonyms SNDX-275

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03018249 Not yet recruiting Grade 1 Endometrial Endometrioid Adenocarcinoma|Grade 2 Endometrial Endometrioid Adenocarcinoma|Grade 3 Endometrial Endometrioid Adenocarcinoma|Uterine Corpus Adenosarcoma National Cancer Institute (NCI) August 2017 Phase 2
NCT02697630 Not yet recruiting Metastatic Uveal Melanoma Vastra Gotaland Region|Merck Sharp & Dohme Corp.|Syndax Pharmaceuticals March 2017 Phase 2
NCT02936752 Not yet recruiting Previously Treated Myelodysplastic Syndrome National Cancer Institute (NCI) March 2017 Phase 1
NCT03024437 Not yet recruiting Metastatic Cancer|Renal Cancer Roberto Pili|Indiana University January 2017 Phase 1|Phase 2
NCT02780804 Recruiting Childhood Brain Stem Neoplasm|Childhood Lymphoma|Childhood Solid Neoplasm|Pineal Region Neoplasm|Recurrent Childhood Central Nervous System Neoplasm|Recurrent Childhood Visual Pathway Glioma|Refractory Central Nervous System Neoplasm National Cancer Institute (NCI) December 2016 Phase 1
NCT02922933 Recruiting Volunteers|Healthy Volunteers|Human Volunteers|Normal Volunteers Syndax Pharmaceuticals November 2016 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Entinostat (MS-275) | Entinostat (MS-275) supplier | purchase Entinostat (MS-275) | Entinostat (MS-275) cost | Entinostat (MS-275) manufacturer | order Entinostat (MS-275) | Entinostat (MS-275) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID